{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:14:47Z","timestamp":1762640087494,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We retrospectively investigated the widely used radiosensitisers cisplatin and mitomycin C\/5-fluorouracil (5-FU) in patients with locally advanced vulvar cancer for outcome and toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We screened the archive for patients treated with chemoradiation for vulvar cancer diagnosed between 01\/2010 and 08\/2021 at our institution. The impact of both radiosensitisers on prognosis was compared using Kaplan\u2013Meier method and Cox-regression analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred and forty-three patients with vulvar cancer were screened. Twenty-nine patients received chemoradiation (mitomycin C\/5-FU <jats:italic>n<\/jats:italic>\u2009=\u200914; cisplatin <jats:italic>n<\/jats:italic>\u2009=\u200912; others <jats:italic>n<\/jats:italic>\u2009=\u20093) as a primary, neoadjuvant or adjuvant treatment. Median follow-up was 15.5\u00a0months. Patients in the cisplatin group were older (mean age 54.4 vs. 70.7; <jats:italic>p<\/jats:italic>\u2009=\u20090.004). However, the mitomycin C\/5-FU group had more advanced tumour stages. The 2-year recurrence-free survival (RFS) was comparable (44.5% vs. 33.3%; <jats:italic>p<\/jats:italic>\u2009=\u20090.932). The 2-year overall survival (OS) showed a numerical but not statistically significant difference in favour of the mitomycin C\/5-FU group (59.7% vs. 31.7%; <jats:italic>p<\/jats:italic>\u2009=\u20090.37). 64.3% (9 out of 14) patients, who received mitomycin C\/5-FU achieved clinical complete response (cCR) compared to 41.7% (5 out of 12) who received cisplatin (<jats:italic>p<\/jats:italic>\u2009=\u20090.505). Radiodermatitis was the most common adverse event in both groups (81%) and more severe in the mitomycin C\/5-FU cohort. Myelotoxicity was frequently observed in both groups. Eighteen patients received an additional radiation boost with 10.0 (9\u201316) Gy and showed a significantly prolonged RFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.027) and OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.003).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Mitomycin C\/5-FU may be considered in the treatment of young and healthy patients with locally advanced vulvar cancer.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04006-0","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T12:02:44Z","timestamp":1650628964000},"page":"1391-1399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of cisplatin and mitomycin C\/5-FU as radiosensitisers in the treatment of locally advanced vulvar cancer: results of a retrospective, observational, single-institutional cohort study"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-5484","authenticated-orcid":false,"given":"Valerie Catherine","family":"Linz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Schwanbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slavomir","family":"Krajnak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Anic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"J\u00e4kel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Schmidberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Hasenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Johannes","family":"Battista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"4006_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/IJWH.S68979","volume":"7","author":"I Alkatout","year":"2015","unstructured":"Alkatout I, Schubert M, Garbrecht N, Weigel MT, Jonat W, Mundhenke C, Gunther V (2015) Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health 7:305\u2013313. https:\/\/doi.org\/10.2147\/IJWH.S68979","journal-title":"Int J Womens Health"},{"issue":"5","key":"4006_CR2","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15(5):2040\u20132049. https:\/\/doi.org\/10.1200\/JCO.1997.15.5.2040","journal-title":"J Clin Oncol"},{"issue":"5","key":"4006_CR3","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.ijrobp.2005.11.007","volume":"64","author":"S Beriwal","year":"2006","unstructured":"Beriwal S, Heron DE, Kim H, King G, Shogan J, Bahri S, Gerszten K, Lee J, Kelley J, Edwards RP (2006) Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome. Int J Radiat Oncol Biol Phys 64(5):1395\u20131400. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.11.007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4006_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1006\/gyno.1997.4758","volume":"66","author":"MJ Cunningham","year":"1997","unstructured":"Cunningham MJ, Goyer RP, Gibbons SK, Kredentser DC, Malfetano JH, Keys H (1997) Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. Gynecol Oncol 66(2):258\u2013261. https:\/\/doi.org\/10.1006\/gyno.1997.4758","journal-title":"Gynecol Oncol"},{"key":"4006_CR5","unstructured":"Dass PH, Kuper-Hommel MJ (2017) A review of squamous cell vulvar cancers in Waikato region, New Zealand. N Z Med J 130(1465): 19\u201328. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29121621"},{"issue":"1","key":"4006_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1006\/gyno.1995.1267","volume":"59","author":"PJ Eifel","year":"1995","unstructured":"Eifel PJ, Morris M, Burke TW, Levenback C, Gershenson DM (1995) Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol 59(1):51\u201356. https:\/\/doi.org\/10.1006\/gyno.1995.1267","journal-title":"Gynecol Oncol"},{"key":"4006_CR7","unstructured":"ESGO-Guidelines (2016) Vulvar-cancer-complete-report-fxd2.pdf; Retrieved from: https:\/\/guidelines.esgo.org\/vulvar-cancer\/guidelines\/recommendations\/, 27.01.2022."},{"issue":"9","key":"4006_CR8","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","volume":"14","author":"M Flam","year":"1996","unstructured":"Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, Murray K (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14(9):2527\u20132539. https:\/\/doi.org\/10.1200\/JCO.1996.14.9.2527","journal-title":"J Clin Oncol"},{"issue":"3","key":"4006_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ygyno.2011.02.005","volume":"121","author":"RG Ghebre","year":"2011","unstructured":"Ghebre RG, Posthuma R, Vogel RI, Geller MA, Carson LF (2011) Effect of age and comorbidity on the treatment and survival of older patients with vulvar cancer. Gynecol Oncol 121(3):595\u2013599. https:\/\/doi.org\/10.1016\/j.ygyno.2011.02.005","journal-title":"Gynecol Oncol"},{"issue":"5","key":"4006_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/s0360-3016(00)00569-1","volume":"47","author":"SC Han","year":"2000","unstructured":"Han SC, Kim DH, Higgins SA, Carcangiu ML, Kacinski BM (2000) Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiat Oncol Biol Phys 47(5):1235\u20131244. https:\/\/doi.org\/10.1016\/s0360-3016(00)00569-1","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"4006_CR11","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/ijc.30900","volume":"141","author":"YJ Kang","year":"2017","unstructured":"Kang YJ, Smith M, Barlow E, Coffey K, Hacker N, Canfell K (2017) Vulvar cancer in high-income countries: Increasing burden of disease. Int J Cancer 141(11):2174\u20132186. https:\/\/doi.org\/10.1002\/ijc.30900","journal-title":"Int J Cancer"},{"issue":"3","key":"4006_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1006\/gyno.1996.0150","volume":"61","author":"F Landoni","year":"1996","unstructured":"Landoni F, Maneo A, Zanetta G, Colombo A, Nava S, Placa F, Tancini G, Mangioni C (1996) Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Gynecol Oncol 61(3):321\u2013327. https:\/\/doi.org\/10.1006\/gyno.1996.0150","journal-title":"Gynecol Oncol"},{"issue":"8","key":"4006_CR13","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1472::AID-CNCR8>3.0.CO;2-E","volume":"77","author":"G Lupi","year":"1996","unstructured":"Lupi G, Raspagliesi F, Zucali R, Fontanelli R, Paladini D, Kenda R, di Re F (1996) Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma a Pilot Study. Cancer 77(8):1472\u20131478. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19960415)77:8%3c1472::AID-CNCR8%3e3.0.CO;2-E","journal-title":"Cancer"},{"issue":"1","key":"4006_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ygyno.2010.09.004","volume":"120","author":"RH Mak","year":"2011","unstructured":"Mak RH, Halasz LM, Tanaka CK, Ancukiewicz M, Schultz DJ, Russell AH, Viswanathan AN (2011) Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. Gynecol Oncol 120(1):101\u2013107. https:\/\/doi.org\/10.1016\/j.ygyno.2010.09.004","journal-title":"Gynecol Oncol"},{"issue":"11","key":"4006_CR15","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","volume":"16","author":"E L\u00e9vy","year":"1998","unstructured":"Meta-Analysis Group In Cancer, L\u00e9vy E, Buyse M, Pignon JP, Rougier P, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, Macdonald J, Benedetti J, Lokich J, Fryer J, Brufman G, Isacson R, Laplanche A, Quinaux E, Thirion P (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16(11):3537\u20133541. https:\/\/doi.org\/10.1200\/JCO.1998.16.11.3537","journal-title":"J Clin Oncol"},{"issue":"3","key":"4006_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ygyno.2011.11.003","volume":"124","author":"DH Moore","year":"2012","unstructured":"Moore DH, Ali S, Koh WJ, Michael H, Barnes MN, McCourt CK, Homesley HD, Walker JL (2012) A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol 124(3):529\u2013533. https:\/\/doi.org\/10.1016\/j.ygyno.2011.11.003","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4006_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/s0360-3016(98)00193-x","volume":"42","author":"DH Moore","year":"1998","unstructured":"Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G (1998) Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 42(1):79\u201385. https:\/\/doi.org\/10.1016\/s0360-3016(98)00193-x","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4006_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ygyno.2004.03.019","volume":"93","author":"N Mulayim","year":"2004","unstructured":"Mulayim N, Foster Silver D, Schwartz PE, Higgins S (2004) Chemoradiation with 5-fluorouracil and mitomycin C in the treatment of vulvar squamous cell carcinoma. Gynecol Oncol 93(3):659\u2013666. https:\/\/doi.org\/10.1016\/j.ygyno.2004.03.019","journal-title":"Gynecol Oncol"},{"issue":"6","key":"4006_CR19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/annonc\/mdq597","volume":"22","author":"G Nagel","year":"2011","unstructured":"Nagel G, Concin H, Bjorge T, Rapp K, Manjer J, Hallmans G, Diem G, Haggstrom C, Engeland A, Almquist M, Jonsson H, Selmer R, Stocks T, Tretli S, Ulmer H, Stattin P, Lukanova A (2011) Metabolic syndrome and rare gynecological cancers in the metabolic syndrome and cancer project (Me-Can). Ann Oncol 22(6):1339\u20131345. https:\/\/doi.org\/10.1093\/annonc\/mdq597","journal-title":"Ann Oncol"},{"issue":"4","key":"4006_CR20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/IGC.0000000000000975","volume":"27","author":"MHM Oonk","year":"2017","unstructured":"Oonk MHM, Planchamp F, Baldwin P, Bidzinski M, Brannstrom M, Landoni F, Mahner S, Mahantshetty U, Mirza M, Petersen C, Querleu D, Regauer S, Rob L, Rouzier R, Ulrikh E, van der Velden J, Vergote I, Woelber L, van der Zee AGJ (2017) European society of gynaecological oncology guidelines for the management of patients with vulvar cancer. Int J Gynecol Cancer 27(4):832\u2013837. https:\/\/doi.org\/10.1097\/IGC.0000000000000975","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"4006_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ygyno.2017.06.022","volume":"146","author":"YJ Rao","year":"2017","unstructured":"Rao YJ, Chin RI, Hui C, Mutch DG, Powell MA, Schwarz JK, Grigsby PW, Markovina S (2017) Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: a review of the National Cancer Database. Gynecol Oncol 146(3):572\u2013579. https:\/\/doi.org\/10.1016\/j.ygyno.2017.06.022","journal-title":"Gynecol Oncol"},{"issue":"3","key":"4006_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4006_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225747","author":"L Tagliaferri","year":"2021","unstructured":"Tagliaferri L, Lancellotta V, Casa C, Fragomeni SM, Ferioli M, Gentileschi S, Caretto AA, Corrado G, Gui B, Colloca GF, Gambacorta MA, Morganti AG, Garganese G, Macchia G (2021) The radiotherapy role in the multidisciplinary management of locally advanced vulvar cancer: a multidisciplinary VulCan team review. Cancers. https:\/\/doi.org\/10.3390\/cancers13225747","journal-title":"Cancers"},{"issue":"1","key":"4006_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/COC.0b013e3181cae6a1","volume":"34","author":"L Tans","year":"2011","unstructured":"Tans L, Ansink AC, van Rooij PH, Kleijnen C, Mens JW (2011) The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature. Am J Clin Oncol 34(1):22\u201326. https:\/\/doi.org\/10.1097\/COC.0b013e3181cae6a1","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"4006_CR25","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/sj.bjc.6600917","volume":"88","author":"NC Tebbutt","year":"2003","unstructured":"Tebbutt NC, Norman AR, Cunningham D, Allen M, Chau I, Oates J, Hill M (2003) Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. Br J Cancer 88(10):1510\u20131515. https:\/\/doi.org\/10.1038\/sj.bjc.6600917","journal-title":"Br J Cancer"},{"issue":"1","key":"4006_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ygyno.2021.07.020","volume":"163","author":"B van Triest","year":"2021","unstructured":"van Triest B, Rasing M, van der Velden J, de Hullu J, Witteveen PO, Beukema JC, van der Steen-Banasik E, Westerveld H, Snyers A, Peters M, Creutzberg CL, Nout RA, Lutgens L, Jurgenliemk-Schulz I (2021) Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study. Gynecol Oncol 163(1):117\u2013124. https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.020","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04006-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04006-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04006-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:59:18Z","timestamp":1679875158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04006-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["4006"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04006-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"assertion":[{"value":"6 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"V.C.L., C.S., J.J., H.S. and M.J.B. have no relevant financial or non-financial interests to disclose. M.S. reports personal fees from AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Roche, and SeaGen outside the submitted work. Institutional research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre Fabre, and SeaGen. In addition, M.S. has a patent for EP 2390370 B1 issued and a patent for EP 2951317 B1issued. SK received speaker honoraria from Roche Pharma AG and Novartis Pharma GmbH Germany, research funding from Novartis Pharma GmbH Germany and travel reimbursement from PharmaMar and Novartis Pharma GmbH Germany. A.H. reports honoraria from AstraZeneca, Celgen, MedConcept GmbH, Med update GmbH, Medicultus, Pfizer, Roche Pharma AG, Streamedup!GmbH, Tesaro Bio Germany GmbH, LEO Pharma, Clovis Oncology. A.H. is ad board for PharmaMar, Roche Pharma AG, Tesaro Bio Germany GmbH, AstraZeneca, LEO Pharma, GSK\/MSD. R.S. received honoraria from Roche Pharma AG, AstraZeneca, Streamedup!GmbH. K.A. received honoraria from Clovis Oncology and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is an observational study and no ethical approval is required. The retrospective cohort study was conducted in accordance with the \u201cEthical principles for medical research involving human subjects\u201d of the current version of the Declaration of Helsinki. Data collected for this study were obtained as part of routine medical care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}